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The mitochondrial oxidative phosphorylation (OxPhos) system plays a key role in energy production, the generation of free radicals, and
apoptosis. A lack of cellular energy, excessive radical production, and dysregulated apoptosis are found alone or in combination in most human
diseases, including neurodegenerative diseases, stroke, cardiovascular disorders, ischemia/reperfusion, and cancer. In the context of its relevance to
human disease, this article reviews current knowledge about the regulation of OxPhos with a focus on cell signaling and discusses identified
phosphorylation sites with the aid of crystal structures of OxPhos complexes. Several recent studies have shown that all OxPhos components can be
phosphorylated; even the small electron carrier cytochrome c is tyrosine phosphorylated in vivo. We propose that in higher organisms, in contrast to
bacteria, cell signaling pathways are the main regulator of energy production, triggered for example by hormones. Pathways that have been identified
to act on OxPhos include protein kinases A and C and growth factor activated receptor tyrosine kinase signaling. Present knowledge about kinases
and phosphatases that execute signals at the level of the mitochondrial OxPhos system, and newly emerging concepts, such as the translocation of
kinases to the mitochondria upon stimulation of a signaling pathway, are discussed.
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Energy homeostasis is a main determinant of survival in all
higher organisms. It has been estimated that an average person
consumes 100 kcal/h at rest, roughly corresponding to the
energy output of a 100 W light bulb or the production of about
65 kg of ATP/day [1]. During exercise these values can increase
many fold. The initial pathway for breaking down carbohy-
drates from food to pyruvate via glycolysis in the cytosol
produces only a small amount of ATP, whereas the oxidation of
pyruvate in the mitochondria provides more than 15 times the
ATP produced by anaerobic glycolysis [2]. In contrast to many
unicellular organisms including yeast, which have evolved
mechanisms allowing them to grow and survive in the absence
of oxygen, animals fully rely on cell respiration. This is so
because the roughly 1014 cells present in a human are not only
highly specialized and energy expensive but cell density is also⁎ Corresponding author. Tel.: +1 313 577 9150; fax: +1 313 577 5218.
E-mail address: mhuttema@med.wayne.edu (M. Hüttemann).
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moval of carbon dioxide through the body's circulation. Thus,
provision of a constant energy supply through glycolysis alone
is not feasible in animals under healthy conditions (theoretical-
ly, one would have to eat constantly), but there are conditions in
which energy is primarily derived from glycolysis, such as seen
in the fetus during the first half of the pregnancy [3] and in
cancer, where it is known as the Warburg effect [4,5]. In both
examples, the rest of the body provides glucose and disposes of
the end product of the glycolytic pathway, lactate, to sustain
growth as long as possible. For its own survival and that of the
mother, the fetus later must switch to aerobic energy production,
whereas cancer if not stopped would eventually starve its host to
death.
Cell respiration takes place in the mitochondria, organelles
the size of bacteria (2–4 μm). The number of mitochondria
varies significantly among cell types. For example it was es-
timated that mammalian hepatocytes and oocytes contain 800
and 100,000 mitochondria, respectively [6]. Mitochondria have
two membranes and contain their own DNA encoding 13
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membrane and are part of the oxidative phosphorylation
(OxPhos) machinery.
OxPhos is a key functional unit in the mitochondria, and
combines electron transport with cell respiration and ATP syn-
thesis (Fig. 1). It not only produces the vast majority of cellular
energy, but is also involved in radical production and apoptosis.
OxPhos consists of the electron transport chain (ETC), which
comprises NADH-dehydrogenase (complex I), succinate dehy-
drogenase (complex II), ubiquinone, bc1 complex (complex
III), cytochrome c (Cyt c), and cytochrome c oxidase (CcO;
complex IV). The majority of electrons transferred by the ETC
are derived from NADH and enter the chain via complex I. In
addition, complex II feeds electrons directly into the ubi-
quinone/ubiquinol pool, and further input sources include the
electron-transferring flavoprotein (ETF), ubiquinone oxidore-
ductase, and glycerol-3-phosphate dehydrogenase. These elec-
trons are transferred through the ETC to oxygen, while the
mitochondrial membrane potential is generated by pumping
protons across the inner mitochondrial membrane. Finally, the
proton gradient is utilized by ATP synthase (complex V), which
couples the backflow of those protons previously pumped by
the ETC to the production of ATP (Fig. 1).
Cellular energy demand ranges widely depending on the
function and activity of the cell. Thus adjustment of energy
production to physiological demand is essential to all higher
organisms. The first mechanism identified by which OxPhos is
controlled is called respiratory control as was shown with iso-
lated mitochondria [7]. Here, OxPhos activity is limited by the
availability of the substrates for ATP synthesis, ADP and phos-
phate. Thus, OxPhos activity increases when ATP utilization
generates ADP and phosphate. In addition to this basic substrate
limitation mechanism there are several further levels of control,
and nature has cultivated three major regulatory means, which
are found alone or in combination (Fig. 1). There are 1) tissue-
specific and/or developmental expression of isozymes, whichFig. 1. Regulation of mammalian oxidative phosphorylation (OxPhos). At the funct
organs express tissue-specific isozymes, hormones mediate signals from the outside of
allows fine-tuning of energy production within the cell IMS: intermembrane space.equip a cell with variants that perform the same chemistry but are
adapted to tissue-specific requirements, 2) allosteric control,
mediated through small molecules that bind to the enzyme,
changing its kinetic properties, and 3) cell signaling. The latter
two mechanisms can be viewed as a hierarchy: allosteric control
represents an intracellular response, for example triggered by
changes in the concentration of substrate or product molecules.
In contrast, cell signaling primarily serves the purpose of higher-
order communication between cells or organs. For example,
glucagon and insulin, released by the pancreatic alpha and beta
cells, respectively, reach their target organs such as liver and
muscle through the blood stream. There, they bind to specific
receptors and trigger an amplification cascade, which eventually
adjusts cell function to the physiological circumstances the
whole organism faces at the time of hormone release. In the
example given glucagon, a starvation signal, is present after
extended periods of food deprivation, e.g., after overnight rest,
and triggers a major metabolic response through the cAMP-
dependent pathway in liver. The liver, as an altruistic organ, then
provides food in the form of glucose for other organs such as the
brain. After ingestion of food insulin is released, signaling that
metabolic building blocks have become available and have to be
taken up by the cells. The effect of insulin is mediated through
the phosphoinositol-3 kinase pathway.
Within the cell there is a sequence of kinases and phos-
phatases, which add or remove phosphate groups from down-
stream kinases and/or phosphatases or endpoint targets. It is
now clear that the traditional view of linear, i.e., hierarchical,
signaling cascades is an oversimplification because there is
considerable crosstalk between different signaling pathways.
This crosstalk sometimes complicates the interpretation of ex-
perimental results and, when overlooked, may also account for
some discrepancies reported in the literature.
Several recent review articles have summarized data on
phosphorylated proteins identified within the mitochondria and
on signaling pathways that act onmitochondria [8–11]. The goalional level OxPhos is regulated through a hierarchy of regulatory mechanisms:
the cell to the mitochondria through signaling cascades, and allosteric regulation
1703M. Hüttemann et al. / Biochimica et Biophysica Acta 1773 (2007) 1701–1720of this article is to provide a focused view of current knowledge
about regulation of the mitochondrial OxPhos system as an
endpoint of cell signaling due to its emerging recognition as an
important factor in human pathophysiology.
2. Cell signaling targets all mitochondrial OxPhos
components in mammals
Partial or complete crystal structures from mammals and/or
homologous structures from bacteria are now available from all
components of the OxPhos system (Fig. 2). They are not only
essential for a better understanding of the catalytic mechanisms
of the individual enzymes but also for the interpretation of
regulatory events. For example, after a phosphorylation site has
been mapped the structural information can be used to interpret
changes in enzymatic properties. Several different types of data
have been acquired in recent years, such as proteomic studies
analyzing protein phosphorylation on a larger scale. Often,
however, the information obtained represents just one piece of
the puzzle. In order to understand the complex regulation of
aerobic energy metabolism the approach must be integrative,
linking a molecular event, such as the attachment of a phosphate
group to a specific amino acid, to functional change, such as
changes in enzyme activity.
We here discuss current knowledge of the regulation of
OxPhos complexes and the physiological relevance of such
regulation. Although many open questions remain, CcO is the
best-studied complex with respect to regulation through isoform
expression, allosteric control, and reversible phosphorylation.
Thus, CcO serves as an example of what can be expected to be
revealed for the entire OxPhos system in the future.
2.1. NADH-dehydrogenase (NADH-DH) (complex I)
With 46 subunits and amolecular weight close to 1MDa [12],
NADH-DH is the most complex OxPhos member and also the
least understood. Recently, a partial crystal structure containing
eight subunits from the hydrophilic arm of complex I from
Thermus thermophilus was resolved [13] (Fig. 2A). This
bacterial enzyme has a smaller number of only 15 subunits, 14
of which have homologs in mammals. Bacterial complex I
presumably lacks several regulatory mechanisms that are yet
to be discovered in mammals, including additional regulatory
subunits, similar to CcO as discussed below.
2.1.1. cAMP-dependent signaling to the mitochondria
The majority of studies of cell signaling targeting ETC
complexes investigated the effect of the cAMP-dependent
pathway. Most effects of increased intracellular cAMP are
mediated through phosphorylation reactions catalyzed by
protein kinase A (PKA), a serine/threonine-specific kinase
[14]. However, it remains to be clarified whether cytoplasmic
PKA can localize to the mitochondrial matrix and/or inter-
membrane space. Several studies have concluded that there was
PKA activity in the mitochondria. For example, incubation of
cow heart mitochondria with cAMP in the presence of [γ-32P]
ATP showed labeling of four proteins [15]. Other studies alsosuggested the presence of PKA in mitochondria of yeast,
mammalian cell lines, and a variety of mammalian tissues [16–
24]. Other studies have provided a different model of action of
cAMP-dependent signaling in the mitochondria. For example,
A-kinase anchoring proteins (AKAPs) have recently gained
much attention because they localize PKA to cellular compart-
ments in close proximity to its targets [25]. Several recent studies
have indicated that AKAPs localize PKA to the outer side of the
outer mitochondrial membrane. In germ cells AKAP84 has been
shown to control the migration of mitochondria from the
cytoplasm in round spermatids to the cytoskeleton in elongating
spermatids [26], and AKAP1-mediated cellular localization of
PKA to the mitochondria is required during oocyte maturation in
mice, which starts 1.5 h after initiation of the maturation process
[27]. Similarly, stimulation of the cAMP pathway in the human
embryonic kidney cell line HEK293 leads to a sub-mitochon-
drial localization of PKA to the outer side of the outer mito-
chondrial membrane, mediated by AKAP84 and AKAP121
[28,29]. At the same sub-cellular location PKA phosphorylates
the proapoptotic protein BAD on serine 112, a process that is
AKAP-mediated [30,31]. In contrast, a recent study on rat heart
mitochondria concluded that AKAP121was localized within the
mitochondria [32].
Possibly, both models co-exist and PKA can modify other
signaling compounds on the outer side of themitochondria, but it
can also translocate into the mitochondria and directly
phosphorylate mitochondrial proteins (Fig. 3). In addition,
tissue-specific differences may favor one mode of action over
the other.
The action and localization of certain kinases, such as PKA,
and the importance of scaffolding proteins, such as AKAPs, for
the convergence and specific targeting of phosphorylation
events to recipient proteins, should always be addressed by in
vivo studies. For example, the combination of a purified OxPhos
complex with a commercially available kinase should be inter-
preted cautiously and should be validated in the physiological
context in vivo (see also section ‘Cytochrome c oxidase’).
cAMP-dependent phosphorylation of complex I was first
studied by the Papa group. They suggested that PKA directly
phosphorylates complex I in heart tissue, leading to enzyme
activation [33,34]. A radioactively labeled band was obtained in
the 18 kDa size range and it was proposed that the N-terminal
sequence containing the AQDQ-18 kDa subunit was targeted for
phosphorylation. cAMP-dependent phosphorylation of an
18 kDa band was also shown in rat C6 glioma cells in cell
culture after treatment with forskolin or dibutyryl-cAMP [35].
However, mapping of phospho-epitopes by mass spectroscopy
was not performed in those studies. Later, using heart sub-
mitochondrial particles and isolated complex I with an in vitro
PKA phosphorylation approach, the Walker lab showed via
mass spectroscopy that under similar conditions, instead of the
AQDQ subunit the N-terminal sequence containing ESSS-
18 kDa subunit of complex I was phosphorylated on serine 20 in
addition to serine 55 of the 10 kDa-MWFE subunit [36] (Fig.
2A). Although the membrane-containing arm of complex I that
contains the ESSS and MWFE subunits has not yet been
crystallized, the phosphorylation sites are likely to be located on
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experiments were performed to address functional consequences
of the dual phosphorylation of complex I.In order to assess in vivo phosphorylation of complex I the
Gibson and Capaldi labs isolated the cow heart enzyme, se-
parated the sample by SDS-PAGE, and stained the gel with the
Fig. 3. Protein kinase A (PKA), Src, and EGFR signaling to the mitochondria.
Upon stimulation of the cAMP-dependent pathway PKA translocates to the outer
site of the outer mitochondrial membrane, which is mediated by A-kinase an-
choring proteins (AKAPs) that provide a signaling hub for additional proteins
including Src kinase. Two models have been suggested for cAMP signaling to the
mitochondria that may co-exist. Catalytic and/or regulatory subunits of PKA
translocate into the mitochondria and are present in the intermembrane and matrix
space (direct model). Alternatively, PKA can activate a downstream kinase (PTK,
protein tyrosine kinase), which then phosphorylates target proteins, such as CcO
(indirect model). PKA and Src inhibit and activate mitochondrial respiration via
phosphorylation of CcO subunits I and II, respectively. Another player appears to
be EGFR, which is phosphorylated by Src, and translocates from the plasma
membrane to the mitochondria where it interacts with but does not phosphorylate
CcO subunit II. It remains to be seen in what compartment phosphorylation of
EGFR occurs, on the outside of the mitochondria perhaps at the AKAP signaling
hub, or separately on the inside.
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Numerous bands were stained even after alkaline phosphatase
treatment, a commonly used control, which nonspecifically
removes phosphate groups; thus the specificity of the probe has
to be further evaluated in future studies. The authors tried to
identify phosphorylated epitopes by tandem mass spectrometry
(MS/MS). Although the ultimate proof through MS/MS se-
quencing was difficult to achieve, they concluded through
indirect controls that the NDUFA10 (42 kDa) subunit was
phosphorylated on serine 59. This residue is not evolutionarily
conserved in mammals and functional implications of its phos-
phorylation have not been addressed yet. Recently, serine 59
phosphorylation in cow heart was confirmed by another pro-
teomic study using isolated complex I followed by mass spec-
trometry [38]. In addition these authors detected a second
phosphorylation site on serine 95 in the B14.5a subunit (Fig. 2A
and Table 1).
Recent advances in technology have made possible phospho-
proteomic studies, which can be applied in a high throughput
fashion. Often 2D gel electrophoresis followed by the iden-
tification of phosphorylated protein spots is combined with MS/
MS to identify phosphorylated peptides and, if possible, to map
phosphorylated amino acids. Identification of phosphorylatedFig. 2. Reversible phosphorylation targets all enzymes of the OxPhos system. Crysta
[13], of complex II from porcine heart [197], of cow heart complex III [48], of hor
complete structure for mammalian ATP synthase is not available yet. In order to prov
from the following parts: FO unit from Escherichia coli [199], F1 and the central stalk
addition. the bacterial δ subunit from E. coli, which is homologous to mammalian OS
revealing this interaction [202]. Crystallographic data were processed with the pr
Identified mammalian phosphorylated amino acids are highlighted in sticks (see also
where the sites remain unknown are indicated (P?).amino acids using mass spectrometry is not routine due to
system-immanent limits, including loss of the unstable phos-
phate moiety after ionization and, often-encountered, low sen-
sitivity. In addition, proteins usually are only partially phos-
phorylated and the unphosphorylated form often represents the
main protein fraction, as was shown with mitochondrial pro-
teins from pig [39] and potato [40]. Therefore, the identification
of enriched phosphorylated proteins is feasible whereas low-
abundance fragments are often missed. Phospho-proteomic
studies with increased sensitivity will play a major role in the
future because they will allow a global assessment of protein
phosphorylation after induction or inhibition of a signaling
pathway. Ideally, those experiments will be accompanied by
functional studies with the ultimate goal of drawing structure–
function relationships.
A recent phospho-proteomic study on porcine mitochondria
using 2D gel electrophoresis, staining of phosphorylated
proteins with Pro-Q-Diamond, and identification of phosphor-
ylated proteins through mass spectrometry suggested phosphor-
ylation of all OxPhos complexes [39] (see also below). For
complex I seven subunits showed Pro-Q-Diamond staining: the
75 kDa Fe–S protein 1, flavoprotein 1, 39 kDa 1α subcomplex,
24 kDa subunit, 23 kDa subunit (mitochondrial precursor),
22 kDa 1β subcomplex, and the 15 kDa subunit. Although no
phosphate groups were assigned to specific amino acids and no
functional studies were undertaken for any of the OxPhos
complexes, this study provides strong evidence that the input
point of the OxPhos system is targeted for regulation via cell
signaling cascades, which would be expected for a key
metabolic enzyme. Phosphorylation of the 39 kDa subunit on
a yet-to-be-identified tyrosine residue was also inferred based on
studies on isolated rat brain mitochondria [41].
An interesting finding was that complex I subunit ND2 seems
to have a second role that, at first sight, appears not to be related
to electron transfer and does not take place in the mitochondria.
In rat ND2 was shown to interact with Src tyrosine kinase at
excitatory synapses, localizing Src to N-methyl-D-aspartate
receptors [42]. The authors found that ND2 was not targeted
for phosphorylation and thus proposed that it functions as an
adaptor protein. It has been shown that Src also localizes to the
mitochondria, in particular to the intermembrane space [43], and
phosphorylates CcO subunit II [44] (Fig. 3). It remains elusive
whether ND2 can also function as a scaffolding protein in the
mitochondria, in which case one would expect that a subunit
near ND2 should be targeted for phosphorylation. A regulatory
action mediated by Src kinase at complexes I and IV would be
physiologically sensible, because it would allow a concerted
change of enzyme activities both at the input point and the
endpoint of the electron transport chain.l structure data of the hydrophilic arm of complex I from Thermus thermophilus
se heart cytochrome c [198], and of cow heart complex IV [76] were used. A
ide a preliminary model partial structures for complex V were modeled together
from cow heart [200], and parts of the peripheral stalk from cow heart [201]. In
CP, was modeled onto the α subunit based on a protein NMR spectroscopy study
ogram Swiss-PDBViewer 3.7 and rendered using the program POV-Ray 3.6.
Table 1). Subunits that have been reported as being phosphorylated in vivo but
Table 1
Identified phospho-epitopes in mammalian OxPhos complexes
OxPhos
complex
Species and tissue Phosphorylated
amino acid
Phospho-epitope Reference Method and comments Kinase prediction a
NADH-DH Cow heart Ser95, B14.5a subunit ASEKKAVSPAPPIKR [38] MSb Cdk5, Cdc2, Erk1,
low confidence
NADH-DH Cow heart Ser59, 42 kDa subunit GNICSGKSKLAKEIA [37,38] MS No known motif
NADH-DH Cow heart Ser20, ESSS (18 kDa)
subunit
TLAGKRPSEPTLRWQ [36] Edman degradation/MS PKA, medium confidence
NADH-DH Cow heart Ser55, MWFE (10 kDa)
subunit
MERDRRVSGVNRSYVS [36] Edman degradation/MS PKA, medium confidence
Cyt c Cow heart Tyr97 EREDLIAYLKKATNE [62] MS No known motif
CcO Cow liver Tyr304, subunit I MDVDTRAYFTSATMI [83] MS, cAMP-dependent No known motif
CcO Rabbit heart Ser115 and Ser116, subunit I SLHLAGVSSILGAINF [118] MS, after
ischemia/reperfusion
No known motif
CcO Rabbit heart Thr52, subunit IV KAPWGSLTRDEKVEL [118] MS, after
ischemia/reperfusion
DNA PK, low confidence
CcO Rabbit heart Ser40, subunit Vb MLPPKAASGTKEDPN [118] MS, after
ischemia/reperfusion
No known motif
CcO Cow heart Thr11, subunit VIa AKGDHGGTGARTWRF [120] Crystal structure No known motif
ATP
synthase
Human skeletal
muscle
Thr213(163) c β subunit GGAGVGKTVLIMELI [137] Indirect No known motif
ATP
synthase
Mouse brain Ser76(33) c α subunit EETGRVLSIGDGIAR [134] BEMADd/MS Akt, Medium confidence
ATP
synthase
Human NIH3T3
cells
Tyr75, δ subunit EDGTTSKYFVSSGSV [133] Indirect,
PDGF-dependent
PDGFR kinase, low confidence
a Based on the Scansite Motif Scan web tool (http://scansite.mit.edu/motifscan_seq.phtml). The predictions are purely speculative and have to be viewed with
extreme caution.
b Mass spectrometry sequencing.
c Numbering according to mature peptide based on cow.
d β-Elimination/Michael addition with DTT labeling.
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of the analogous plastid NADH-DH can be strongly increased
upon stimulation with H2O2 or Ca
2+. This is mediated
through threonine phosphorylation of the NDH-F subunit and
maximal enzyme activity correlates with full phosphorylation
[45].
So far, no tissue-specific subunit isoforms of complex I have
been identified, although there is evidence of functional tissue-
specific differences. Recently, the Villani group has shown
variability of the P/O ratio (moles of ATP synthesized from
ADP per 2 electrons flowing through the ETC), a measure of the
efficiency of OxPhos. Comparison of rat brain, heart, and liver
mitochondria revealed P/O values of 2.0, 2.8., and 2.6, res-
pectively with complex I substrates but no differences were
observed with complex II substrates suggesting that the site
responsible for P/O variability is complex I [46]. The authors
hypothesized that the low P/O ratio found in the brain might
convey neuro-protection, because a higher rate but lower yield
would accommodate the high energy demand of the brain and at
the same time lower intracellular oxygen concentrations, the
substrate for ROS production. Although the underlying mecha-
nisms for P/O variability are unclear, differences in complex I
phosphorylation in addition to tissue-specific subunit isoforms
might account for those observations.
2.2. Succinate dehydrogenase (SDH, complex II)
The four-subunit SDH complex is part of the Krebs cycle and
oxidizes succinate to fumarate, feeding the released electronsinto the ETC. In contrast to the other ETC complexes, SDH does
not pump protons across the inner mitochondrial membrane and
therefore does not contribute to the generation of the
mitochondrial membrane potential. Very little is known about
the regulation of complex II, which is surprising since it integ-
rates Krebs cycle metabolism into the ETC. Indeed, complex II
seems to be regulated through cell signaling, as was recently
indirectly demonstrated in plant and animal mitochondria by
assigning complex II subunits that can be phosphorylated. 2D
gel electrophoresis of isolated mitochondrial porcine proteins,
followed by Pro-Q-Diamond staining, and identification of
phosphorylated proteins via mass spectrometry, suggested phos-
phorylation of the flavoprotein precursor subunit and the iron
sulfur cluster containing B subunit [39] (Fig. 2B). In potato
tubers 14 mitochondrial phospho-proteins were identified after
incubating intact isolated mitochondria with [γ-32P]ATP,
followed by 2D gel electrophoresis and MS/MS analysis of
labeled spots [40]. Among those proteins identified were no
subunits of complex I whereas the flavoprotein (A subunit) of
complex II was radioactively labeled (Fig. 2B). A third study
with the goal of identifying posttranslational modifications on
complexes II and III reported several modifications, including
N-terminal acetylation and oxidation of methionines [47]. How-
ever, the study failed to detect a single phosphorylated peptide,
which may be explained by the omission of the calcium chelator
EGTA and phosphatase inhibitors during mitochondria isola-
tion. Under such conditions calcium activated phosphatases
appear to prevail, leading to dephosphorylation of most mito-
chondrial proteins [39].
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Complex III catalyzes the transfer of electrons from reduced
ubiquinone to oxidized Cyt c via a Q-cycle mechanism, which
leads to the translocation of protons across the inner mitochon-
drial membrane. The mammalian enzyme contains 11 subunits
per monomer but functions as a dimer, which was confirmed by
the X-ray crystal structure [48]. Hardly anything is known about
regulatory mechanisms acting on this enzyme. A phospho-pro-
teomic study already discussed in the previous section indicated
phosphorylation of the β-mitochondrial processing peptidase
(β-MPP) subunit in potato [40], and the porcine heart core
protein I precursor, core protein II, Rieske iron sulfur protein
precursor, and ubiquinone binding protein [39] (Fig. 2C).
Phosphorylated amino acids, relevant signaling pathways, and
effects of those phosphorylations remain elusive.
2.4. Cytochrome c (Cyt c)
The one-electron carrier Cyt c is located in the mitochondrial
intermembrane space and shuttles electrons from bc1 complex
to cytochrome c oxidase. Cyt c from human, cow, and mouse
contains 104 amino acids and a covalently linked heme group.
The heme iron is further coordinated by histidine 18 and
methionine 80. Cyt c is highly positively charged with a pI of 9.6.
Cyt c is essential for aerobic energy production and Cyt c
knockout mice die around midgestation [49]. This is plausible
because at that developmental stage energy production that relies
only 5% on aerobic metabolism before gestation day 9 switches
to aerobic energy metabolism relying 95% on OxPhos after ges-
tation day 11, as was demonstrated with cultured rat embryos [3].
In addition to its essential role in aerobic energy metabolism,
Cyt c also participates in type II apoptosis that involves the
release of Cyt c into the cytosol, which binds to Apaf-1, leading
to activation of procaspase-9 to caspase-9 [50]. Although not
understood in detail, the release of Cyt c into the cytosol is
considered a crucial proapoptotic signal [51,52]. Interestingly,
Cyt c has a third function as a cardiolipin peroxidase at early
stages during apoptosis, where it selectively oxidizes cardiolipin
[53], a lipid of the mitochondrial inner membrane that binds to
Cyt c. This mechanism may play an important role in the release
of Cyt c after the induction of apoptosis, which requires disso-
ciation from the inner mitochondrial membrane. In contrast, a
fourth function as a reactive oxygen species scavenger has been
proposed for Cyt c under normal (non-apoptotic) conditions [54].
Cyt c has a testes-specific isoform in rodents [55], which is
mainly expressed in spermatocytes and cells in the later stages of
spermatogenesis, whereas Sertoli cells, spermatogonia, and
interstitial cells express the otherwise ubiquitously expressed,
so-called somatic Cyt c isoform [56], and both isoforms are
gradually expressed in intermediate cells during sperm matura-
tion [57]. Testes-specific Cyt c has an interesting feature in that it
shows a threefold increased activity to reduce hydrogen pe-
roxide compared with the somatic isoform, but also shows a
three to fivefold activity to induce apoptosis [58]. The authors
concluded that the first effect protects sperm from radical da-
mage whereas the second effect is part of a suicide mechanism ofmale germ cells, which selects for functional and undamaged
sperm. However, the syntenic region of testes Cyt c in the human
genome contains a non-transcribed pseudogene [59], and it
remains elusive whether humans converge the functions of the
somatic and sperm-specific Cyt c variants found in rodents into a
single protein expressed in all human tissues.
One means of Cyt c regulation has been known for three
decades: ATP binds to Cyt c at physiological concentrations,
which affects the binding of Cyt c to CcO, leading to an inhi-
bition of the reaction between Cyt c and CcO, and the elimi-
nation of the low Km phase of the otherwise biphasic kinetics
with CcO [60]. An ATP binding site was later mapped to the
conventional “left side” of the molecule [61]. A similar regu-
latory mechanism is present in CcO as discussed below that also
leads to an inhibition of respiration.
A novel regulatory means mediated by phosphorylation was
recently discovered by our group [62]: Cyt c isolated from cow
heart tissue under conditions that preserved the physiological
phosphorylation state revealed phosphorylation on tyrosine 97,
as shown by tandem-MS. Clear differences were observed in
respiration with CcO, which was inhibited in the presence of
tyrosine 97-phosphorylation and showed pronounced sigmoidal
kinetics [62]. The inhibitory effect of tyrosine 97-phosphory-
lation on respiration with CcO was surprising because tyrosine
97 does not directly participate in Cyt c–CcO binding [63]. In
addition, there are many studies where basic residues of Cyt c
were modified into neutral or acidic moieties [64–66], with the
most dramatic changes in enzyme kinetics being observed when
amino acids were altered that directly participate in binding.
However, the localization of tyrosine 97 in the midst of the only
relatively hydrophobic region on Cyt c [67] might explain far-
reaching structural disturbances ranging to the other side of the
molecule, as was deduced from a spectral shift of the heme
iron–methionine 80 absorption band from 695 to 687 nm [62].
Several questions related to Cyt c phosphorylation remain
open due to its other functions. We have proposed that tyrosine
97 phosphorylation may affect apoptosis [62] because an essen-
tial residue for the interaction with Apaf-1, lysine 7, is spatially
located next to tyrosine 97 [68]. Based on structural considera-
tions the formation of a salt bridge is possible that would
neutralize the positive charge of lysine 7, which might prevent
apoptosome formation. In addition, a conformational change in
Cyt c was earlier observed in apoptotic cells [69], which could
be explained with a change of the phosphorylation status.
Tyrosine 97 phosphorylation might also affect the cardiolipin
peroxidase activity of Cyt c. The Kagan lab has shown that this
mechanism involves a tyrosine radical [53]. In addition, lipid
binding capability would be required that could be provided by
this relatively hydrophobic area [67,70]. However, there are
three additional conserved tyrosine residues in mammalian Cyt
c as potential candidates for the chemistry involved, and more
experiments are needed to decide this issue.
2.5. Cytochrome c oxidase (complex IV; CcO)
CcO is the terminal enzyme of the electron transport chain. It
accepts electrons from reduced Cyt c and transfers them to
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requires protons that, taken up from the matrix, contribute to the
generation of the mitochondrial membrane potential. In addition
to those chemical protons, CcO pumps protons across the inner
mitochondrial membrane, a process that is still not fully un-
derstood and is a matter of intense debate [71–75]. Mammalian
CcO has been crystallized as a dimer, which is composed of 13
subunits per monomer [76]. In addition to the 3 largest mito-
chondrial encoded subunits, which contain the 4 catalytic redox
centers, the mammalian enzyme contains 10 nuclear encoded
subunits. The function of the nuclear encoded subunits and their
isoforms remains largely unknown. However, several studies
have started to shed light on some of those, and thus regulation of
CcO has been studied in more detail compared to the other
OxPhos complexes. These studies provide a preliminary taste of
what may be revealed in the future for the entire OxPhos system.
CcO shows all three regulatory features found in key metabolic
enzymes: isoform expression, allosteric control, and phosphor-
ylation (Fig. 1).
2.5.1. Isoforms
There are three liver- and heart-type isoform pairs of subunits
VIa, VIIa, and VIII, which have been known for several decades
(reviewed in [77]). Liver-type CcO is expressed in organs such
as liver, kidney, and brain, whereas the heart-type isozyme is
expressed in heart and skeletal muscle. In addition, three more
isoforms were discovered recently. These are a lung-specific
isoform of CcO subunit IV, a testes-specific isoform of subunit
VIb, and a third isoform of subunit VIII [59,78,79]. There is
only one published knockout mouse model, which lacks the
subunit VIa heart-type isoform. The mice are viable under no-
stress conditions, but showed only 23% CcO activity in heart
tissue compared to the wild-type, which correlated with reduced
CcO amount (23%) [80].
Functional data including enzyme kinetics have so far been
reported only for the better-studied liver- and heart-type CcO
isozymes. Older studies tried to analyze differences between the
two major isozymes (e.g., [81,82]) but no consistent results
were obtained. The Avadhani lab used sub-mitochondrial par-
ticles and reported a Km for Cyt c of 26 and 8 μM and maximal
turnover values of 495 and 750 s−1 at high ionic strength for
heart and liver CcO, respectively. These data are in agreement
with the idea that heart-type CcO is found in tissues with a high
aerobic capacity and a large number of mitochondria, whereas
other tissues including the brain cannot afford such a high
mitochondrial mass due to their specialized functions, but still
fully depend on aerobic energy production, which requires a
more active enzyme. However, CcO kinetics may have to be re-
evaluated for two reasons: 1) as discussed below, phosphory-
lation of CcO that decisively regulates enzyme activity has to be
considered; this requires isolation conditions that preserve the
physiological phosphorylation status [83], and 2) some
components commonly used during enzyme isolation or during
activity measurements have to be carefully considered. Exam-
ples include the detergent cholate that strongly binds to and
activates CcO, which has to be removed by dialysis [76]; the
detergent dodecylmaltoside that was suggested to monomerizeCcO [84]; and N,N,N′,N′-tetramethyl-p-phenylendiamine
(TMPD), which facilitates electron transfer between molecules
and thus alters enzyme kinetics because Cyt c does not have to
dissociate from CcO in order to be re-reduced [60]. Therefore, it
would be desirable to develop a generally accepted and applied
protocol.
2.5.2. Allosteric control
The largest nuclear encoded subunit, CcO IV, has been
shown to bind ATP at the matrix side, leading to an allosteric
inhibition of enzyme activity at high intra-mitochondrial ATP/
ADP ratios, adjusting energy production to the physiological
demand [85,86]. Computer modeling of an ATP molecule into
a pocket comprised of subunit IV and the catalytic subunits I
and II supported these findings [78]. It was then postulated
that CcO IV is a pivotal regulator of CcO activity in higher
organisms and yeast in contrast to bacteria, which lack this
subunit [87].
Subunit Va, which has no transmembrane helix and localizes
to the matrix site, was shown to bind the thyroid hormone T2,
releasing the allosteric ATP inhibition, and allowing a high
turnover even at a high ATP/ADP ratio [88].
The muscle specific isoform of subunit VIa was suggested to
decrease the pumped proton to electron stoichiometry at high
ATP/ADP ratios [89]. In contrast, CcO containing the VIa liver-
type isoform pumps protons at a high ratio in the presence of
cardiolipin independently of the ATP/ADP ratio, whereas the
addition of palmitate leads to a decreased proton/electron stoi-
chiometry [90].
There are several studies using protein interaction techniques
that suggest additional regulatory means, which need further
investigation. CcO subunit II was shown to bind to the epidermal
growth factor receptor (EGFR) by phage display screening and
co-immunoprecipitation [91]. EGFR signaling is involved in
important cellular processes, such as survival, proliferation, and
migration. Binding of EGFR to CcO subunit II requires tyrosine
845 phosphorylation on EGFR, which is mediated by c-Src,
suggesting that EGFR and c-Src act synergistically (Fig. 3). This
idea is further supported by the fact that CcO subunit II is a target
of c-Src [44], as detailed below.
Another physical partner of CcO subunit II is cyclin G1,
which was demonstrated by yeast two-hybrid work and con-
firmed by co-immunoprecipitation in an osteosarcoma cell line
that overexpresses cyclin G1 [92]. The authors proposed that
cyclin G1, which is induced by tumor suppressor p53, might
participate in the induction of apoptosis through its interaction
with CcO.
Subunit Vb, which similarly to subunit Va localizes to the
mitochondrial matrix side, was shown by a yeast two-hybrid
screen to interact with the cytosolic human androgen receptor
[93]. In addition, it was reported for the RIα regulatory subunit
of PKA that it can also bind to CcO subunit Vb [94]. The
authors concluded that activation of the cAMP pathway using
adenylyl cyclase activator forskolin leads to CcO inhibition
through this direct interaction. As discussed below, it is now
evident that the cAMP-dependent pathway leads to phosphor-
ylation of CcO, which strongly inhibits enzyme activity [83].
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Over the last two decades the work of many labs has
established the importance of NO action on mitochondrial
function, which cannot be addressed here in detail (for reviews
see references [95–97]). NO is synthesized by three types of
NO synthases (NOS), a neuronal (nNOS) and an endothelial
NOS (eNOS) isoform that are constitutively expressed, and an
inducible form (iNOS). Interestingly, a subtype of nNOS
localizes to the mitochondria and was therefore denoted
mitochondrial NOS (mtNOS) [98]. mtNOS can directly interact
with CcO on the matrix side by binding to subunit Va [99],
which increases local concentrations of NO at its target enzyme.
Mechanistically, NO competes with oxygen at the binuclear
heme a3-CuB binding site, which leads to reversible CcO
inhibition [100,101]. Increased cellular NO levels coincide with
many human diseases, including arthritis [102], sepsis and
septic shock [103], trauma [104], cancer [105], obesity, and
diabetes [106]. Despite other actions of NO in the cell its
inhibitory action on CcO might at least in part explain some
aspects of NO-related pathological conditions, because inhibi-
tion of oxidative energy production would decrease cellular
energy levels. The inhibitory effect on cell respiration has also
been proposed as a general mechanism underlying neurode-
generative diseases mediated by an over-production of NO
[107].
2.5.4. Calcium and zinc binding sites
Mammalian CcO contains a calcium–sodium exchange site
in subunit I [108], whereas in bacteria this site contains a
strongly bound calcium [109]. The function of reversible cal-
cium binding is unknown. There have been reports indicating
that CcO can bind at least two zinc ions at two different sites,
which leads to enzyme inhibition and particularly to inhibition of
the proton pumping process [110–112]. It is unclear where
variation of zinc concentrations may affect CcO activity, and
whether zinc really constitutes a physiological regulator. Per-
haps it might play a role for the regulation of sperm motility
before and after ejaculation in testes, which have higher zinc
levels compared to other tissues. That would be sensible because
CcO activity would be down-regulated during periods of quie-
scence whereas zinc ions would be diluted after ejaculation and
allow aerobic energy production when needed. Interestingly,
reduction of zinc concentration clearly improves sperm motility,
and it was concluded that this effect was related to improved
mitochondrial performance [113].
2.5.5. Phosphorylation of CcO
Only during the last few years has it become evident that CcO
can be phosphorylated at several subunits and it is likely that
this mechanism plays the pre-eminent role in regulating enzyme
activity.
The first report indicating CcO phosphorylation was
published by Steenaart and Shore [114]. The authors labeled
mitochondrial proteins phosphorylated by endogenous kinases
using [γ-32P]ATP and concluded that CcO subunit IV can be
phosphorylated. However, the identification of a phosphorylat-
ed residue and possible functional effects still remain elusive.The Kadenbach lab isolated CcO from cow heart and in-
cubated the solubilized enzyme with commercially available
PKA, cAMP, and [γ-32P]ATP [115]. After SDS-PAGE and
autoradiography they observed a signal for subunit Vb and a
faint signal for subunits II or III. Later, applying the same in
vitro approach they presented data suggesting that subunit I was
also phosphorylated [116]. These experiments demonstrate the
modification of heart CcO by PKA in vitro both on the inter-
membrane and matrix side of the enzyme. Functional studies
showed that the in vitro phosphorylated CcO was inhibited
[115]. The Avadhani lab recently reported phosphorylation of
CcO subunits I, IV, and Vb after ischemia in rabbit hearts, and
they proposed that PKA directly phosphorylates CcO under
those conditions because phosphorylation was abolished in the
presence of PKA inhibitor H89 [117]. They later assigned the
phosphorylated amino acids by mass spectrometry to serines
115 and 116 of subunit I, threonine 52 of subunit IV, and serine
40 of subunit Vb [118]. The sites identified (Table 1) are not
PKA consensus sites, suggesting that PKA acts upstream or,
more likely, that the inhibitor H89 also targets one or more other
kinases that mediate those phosphorylations.
Since in vivo phosphorylation sometimes requires auxiliary
proteins for specific targeting of the signal, such as AKAPs in
case of PKA, other labs have started to evaluate cAMP-depen-
dent signaling in a more physiological context. To address this
point, our group initially focused on liver instead of heart tissue.
The starvation hormone glucagon is the strongest physiological
signal for increasing intracellular cAMP levels in liver without
affecting other signaling pathways [119]. In heart there is no
such exquisite trigger, and G-protein linked receptor-mediated
increase of cAMP often parallels an increase in calcium.
Therefore, liver CcO was isolated in the presence or absence
of theophylline, a phosphodiesterase inhibitor that creates high
cAMP levels, and the phosphorylation status was preserved by
the addition of phosphatase inhibitors [83]. High cAMP
produced an enzyme that was tyrosine phosphorylated on
subunit I in vivo whereas the control enzyme did not show a
signal. Subunits II or III and IV were also tyrosine phosphor-
ylated, but there was no change after theophylline treatment.
The site of phosphorylation was identified by mass spectrom-
etry to be CcO subunit I tyrosine 304 (Fig. 2D). Phosphorylated
CcO was fully or strongly inhibited up to 10 μMCyt c substrate
concentrations, even in the presence of allosteric activator ADP
[83]. Treatment of liver tissue or human liver cancer HepG2
cells with the physiological hormone glucagon or the adenylyl
cyclase activator forskolin, which both increase intracellular
cAMP, produced a similar response. Interestingly, theophyl-
line, which is one of the oldest anti-asthma drugs, also led to
CcO inhibition and lowered ATP levels in the lung at
concentrations used in therapy. It was then proposed that this
mechanism might explain the effect of theophylline on asthma
relief because airway constriction during asthma requires
energy [83].
Although the above studies clearly show that cAMP sig-
naling leads to CcO inhibition, in vivo tyrosine 304 phosphory-
lation of liver CcO contrasts with in vitro phosphorylation of
heart CcO using PKA, which is a serine/threonine kinase and
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ates a downstream tyrosine kinase, which then phosphorylates
CcO subunit I. In addition there might be tissue-specific differ-
ences in PKA signaling to the mitochondria, and PKA might
localize to the inner compartments of the mitochondria in some
tissues, such as heart as was proposed for complex I phospho-
rylation in that tissue (see Section 2.1). There is clear evidence
that signaling pathways can operate differently in different
tissues. The presence or absence of kinases and phosphatases,
and tissue-specific expression of isoforms that may in one case
but not in the other be targeted by cell signaling pathways, can
account for tissue-specific differences. Examples are tyrosine
phosphatase PTP 1B, which localizes to the mitochondria, and
is only found in brain but is absent in muscle, heart, and liver
tissue [41], and CcO subunit VIa, which occurs as a pair of
liver- and heart-type isoforms: based on a high resolution crystal
structure Yoshikawa and coworkers were able to show that the
VIa heart isoform is threonine 11 phosphorylated [120] (Fig.
2E), which was confirmed by mass spectrometry (S. Yoshi-
kawa, personal communication). The role of tissue-specific
CcO subunit isoforms is still under debate. The presence or
absence of a kinase motif as observed for the CcO VIa isoform
pair may be revealed as a common theme allowing tissue-
specific regulation through cell signaling.
In addition to cAMP-dependent signaling, Miyazaki and
coworkers have shown that CcO subunit II can be phosphory-
lated by non-receptor tyrosine kinase c-Src in osteoblasts, a
process that appears to be important for the bone-resorbing
activity of these cells, which might be altered in rheumatoid
arthritis [44,121]. The authors found a positive correlation bet-
ween CcO activity and c-Src kinase activity but the phosphory-
lated tyrosine residue remains unknown. Src is involved in
several cellular processes including cell adhesion, movement,
and proliferation.
Another interesting regulator of CcO is protein kinase Cɛ
(PKCɛ), which emerges as a target for hypoxic preconditioning.
Studies on rat neonatal cardiac myocytes using the PKC activ-
ators diacylglycerol or 4β-PMA resulted in the phosphorylation
of an 18 kDa protein in vitro [122,123]. These studies revealed
that PKCɛ co-immunoprecipitated with CcO and that the
radiolabeled 18 kDa band contains subunit IV, as was shown by
mass spectrometry. The phosphorylation site was not assigned
but stimulation of PKCɛ resulted in about two- to fourfold
activation of CcO. Src kinase is also phosphorylated by PKCɛ,
which leads to activation [124,125]. However, no tyrosine
phosphorylation of CcO subunit II was observed after PKCɛ
stimulation [123]. Perhaps this can be explained with tissue-
specific differences in cell signaling involving additional auxi-
liary components in some tissues.
2.6. ATP synthase (complex V)
ATP synthase utilizes the proton gradient generated by the
ETC in order to produce ATP from ADP and phosphate. The
enzyme is a nano-motor consisting of a soluble component, F1,
which is in the matrix and contains the catalytic ATP/ADP/Pi
binding sites, and a membrane bound FO part that couples protonbackflow to ATP synthesis through a peripheral and a rotating
central stalk [126,127]. The F1 part consists of five subunits with
the stoichiometry α3β3γδɛ and the core FO part contains sub-
units ab2c10–14, the so called oligomycin sensitivity-conferring
protein (OSCP), and subunits d, e, f, g, F6, and A6L. Several
partial crystal structures including the F1 component from
mammals and parts of FO from bacteria have been resolved and
are presented as a combined structure in Fig. 2F.
The activity of ATP synthase is dependent on ΔΨm and
maximal rates of ATP synthesis in bacteria occur atΔΨm=100–
120 mV, as has been demonstrated for ATP synthases from
E. coli and P. modestum [128].
In mammals there is so far no evidence for tissue-specific or
developmentally regulated isoforms. However, three isoforms of
the β subunit have been identified in tobacco plants, two of
which seem to be ubiquitously expressed and the third one ex-
clusively expressed in pollen [129]. Since tissue-specific iso-
zymes of ATP synthase have hardly been studied, and consi-
dering the numerous isoforms of CcO subunits, the presence of
isoforms in plants probably just represents the tip of the iceberg
and much more remains to be learned about tissue-specific
energy requirements at the level of this central enzyme.
In order to prevent wasteful ATP hydrolysis a small 10 kDa
inhibitory protein IF1 binds to the soluble F1 component [130].
In addition to the transmembraneous subunits e and g, IF1 also
mediates ATP synthase dimer formation [131].
In 1995 the first study was published showing that ATP syn-
thase can be phosphorylated on the δ subunit in cultured mouse
cortical neurons, triggered by platelet-derived growth factor
(PDGF) [132]. The δ subunit is part of the central rotating stalk,
and phosphorylation can be expected to lead to changes in en-
zyme activity, but additional experiments are needed. The
Pedersen lab later extended those initial data and demonstrated
that PDGF-mediated phosphorylation of the δ subunit also
occurs in NIH3T3 and kidney cells, and the authors provided
indirect evidence that this phosphorylation occurs on the only
tyrosine residue present in this subunit, tyrosine 75 [133] (Fig.
2F). Growth hormone receptor-triggered signaling to the mito-
chondria may also affect other OxPhos complexes, because it
leads to proliferation and cell survival, and Cyt cmight be a first
target to look at due to its participation in apoptosis and the fact
that it can be phosphorylated.
Using mouse brain tissue, a recent phospho-proteomic study
applying an improved protocol called BEMAD (β-Elimination/
Michael addition with DTT labeling) for the detection of
phospho-peptides identified Ser76 of the alpha subunit as being
phosphorylated [134] (Fig. 2F).
There is plenty of evidence that phosphorylation can occur on
additional sites of ATP synthase in mammals, yeast, and plants.
After in vitro incubation of potato tuber inside-out sub-mito-
chondrial particles with [γ-32P]ATP the δ subunit was labeled in
addition to the b subunit, which is part of the peripheral stalk
[135]. A similar approach using intact potato tuber mitochondria
revealed phosphorylation of the α and β subunits [40], which
comprise the catalytic F1 part. A recent study of thylakoid ATP
synthase from barley resolved six variants of theβ subunit on 2D
gels caused by differences in serine/threonine phosphorylation
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four phosphorylated variants were identified after incubation of
cultured skeletal myoblasts with [γ-32P]ATP, followed by 2D gel
analysis [137]. The authors provided some evidence that threo-
nine 213, which is located in the catalytic nucleotide-binding
site, is one phosphorylation site (Fig. 2F). The study also showed
that, at least under cell culture conditions, the unphosphorylated
β subunit was undetectable.
Other studies using Western blot analysis and anti-phospho
tyrosine antibodies on rat brain mitochondria indicated phos-
phorylation of the α and γ subunits [41], whereas Pro-Q-
Diamond staining of porcine mitochondrial proteins pointed to
phosphorylation of the mature peptides of the α and OSCP
(oligomycin sensitivity-conferring protein) subunits [39].
Interestingly, even for yeast, which was long considered a
“zero background” organism for tyrosine phosphorylation
studies, it was recently shown to contain phosphorylated
tyrosine residues on the α and β subunits (yeast nomenclature:
ATP1p and ATP2p) in addition to phosphorylated serine and or
threonine residues [138]. Using MALDI-FTICR-MS (matrix-
assisted laser desorption/ionization Fourier transform ion
cyclotron resonance mass spectrometry), the authors were
able to map specific phosphorylation sites to tyrosine 434 and
serines 413 and 426 of the α subunit, and tyrosine 7 of the β
subunit. However, there was some ambiguity because anti-
phospho antibodies did not show a signal for the α subunit
[138]. Such results might be explainable because mass
spectrometry and immunological approaches show varying
sensitivity to differentiating phosphorylated and unphosphory-
lated peptide species. For example, ionization during mass
spectrometry often leads to loss of a phosphate group and
antibodies may require adjacent amino acids in addition to the
phosphorylated amino acid in order to bind, a problem
especially encountered with anti-phospho-serine and
-threonine antibodies, whereas the phospho-tyrosine group
appears to be a big enough epitope for specific recognition.
Clearly, comprehensive mapping of phosphorylation sites
and functional studies are necessary to understand regulation of
ATP synthase in light of cell signaling.
3. OxPhos supercomplexes
There is now ample evidence that the OxPhos machinery is
organized into higher-order complexes. ATP synthase from rat
liver has recently been shown to co-purify with the phosphate
and the adenine nucleotide carriers, which provide ATP
synthase with its substrates ADP and phosphate [139,140].
Another interesting aspect of ATP synthase is its occurrence in
dimeric and oligomeric states, which was demonstrated for
several organisms including yeast and mammals [141–144],
and it was proposed that cristae morphology is dependent on
these states. Yeast mutants of the e and g subunits, in which the
dimeric and oligomeric states of ATP synthase are destabilized,
showed reduced levels of mitochondrial membrane potential,
which could not be explained through uncoupling of the mem-
brane or activity changes of OxPhos complexes [145]. How-
ever, the phosphorylation state of ATP synthase and of the otherOxPhos complexes was not preserved during mitochondria
isolation, which might explain those findings. The Lippe group
recently speculated that under physiological conditions mono-
meric and oligomeric states might be regulated through phos-
phorylation and they performed 2D gel analysis of monomeric
and dimeric ATP synthase followed by Western analysis with
anti-phospho tyrosine antibodies [146]. The authors found that
the γ subunit was tyrosine phosphorylated only in the mono-
meric but not in the dimeric state. Although the phosphorylated
tyrosine residue remains unknown this work suggests that not
only oligomeric states of ATP synthase but also aggregation of
the other members of the OxPhos machinery into supercom-
plexes may be regulated through cell signaling. Interestingly,
tyrosine 304 phosphorylation of CcO subunit I resulted in
enhanced sigmoidal kinetics and resulted in a Hill coefficient of
about 4 in contrast to a value of 2 for the tyrosine 304 unphos-
phorylated enzyme [83]. One interpretation of an increased Hill
coefficient would be an increase in monomer–monomer inter-
action in the CcO dimer, and it will therefore be interesting to
see if such phosphorylation affects the stoichiometry of CcO in
OxPhos supercomplexes.
Many studies on larger aggregates of OxPhos complexes
employed methods developed by Schägger and coworkers, blue
native and more recently clear-native gel electrophoresis
[147,148], which allows the separation of higher-order super-
complexes under comparably gentle conditions using mild
detergents, such as digitonin. Various stoichiometries of OxPhos
components in supercomplexes have been observed in yeast,
plants, andmammals, including the following variants: I–III2, I–
III2–IV, I–III2–IV2, I–III2–IV3, I–III2–IV4 (for current reviews
see [149–151]). The arrangement of OxPhos complexes into
assembly lines would make possible a more efficient electron
transfer due to substrate channeling. This would be especially
beneficial to speed up energy production in conditions that
require increased ATP production, such as during exercise. Not
only electron transfer might be affected but also the backflow of
protons through the OxPhos complexes (intrinsic uncoupling)
and the production of reactive oxygen species (ROS) as a
byproduct of the OxPhos machinery might be altered. It has
been postulated that intrinsic uncoupling is a mechanism
involved in processes such as thermogenesis [152], and ROS
are important in cell signaling including the induction of
apoptosis [153]. Thus, changes in supercomplex stoichiometry,
probably regulated by cell signaling, and their functional
consequences seem to be an interesting new avenue for future
research.
Cardiolipin is an important mitochondrial lipid, which cons-
titutes about 20% of lipids in the inner mitochondrial membrane.
It was shown for bc1 complex and CcO that cardiolipin stabilizes
supercomplexes in yeast [154,155]. In humans there is a rare
recessive X-linked disease, Barth syndrome, with variable sym-
ptoms including motor delays, hypotonia, delayed growth, and
cardiomyopathy, which is caused by mutations in the cardiolipin
synthesis pathway [156]. A recent study on lymphoblasts from
patients with Barth syndrome carrying mutations in the TAZ1
gene revealed labile supercomplexes of complexes I, II, and IV
[157].
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Cell signaling affects mitochondria through direct phosphor-
ylation and dephosphorylation of mitochondrial proteins, or
through changes in regulation of gene expression of proteins that
localize to the organelle. An example of the latter case is
contractile activity in skeletal muscle, which is paralleled by
increased calcium fluxes, and leads to activation of a series of
kinases including PKC, extracellular signal-regulated kinases
ERK-1 and ERK-2, and ribosomal S6 kinase (reviewed in
[158]). The important role of calcium in gene regulation was
demonstrated in myotubes using calcium ionophore A23187,
which induced the expression of Cyt c and CcO subunit Vb
genes and was mediated by a PKC-dependent pathway [159].
Contractile activity also leads to the induction of peroxisome
proliferator activated receptor co-activator 1α (PGC-1α), a key
nuclear factor that coordinates the expression of nuclear encoded
genes that function in the mitochondria [160]. Another
independent mechanism altering mitochondrial biogenesis
after chronic contractile activity is an acceleration of protein
import into the mitochondria [161].
However, little is known about mitochondrial kinases and
phosphatases, their OxPhos substrates, and the transduction of
the signal from the cytosol to the mitochondria. Based on se-
lected examples we will outline emerging principles of such
signaling relevant to OxPhos. For recent comprehensive reviews
of kinases and phosphatases that have been associated with
mitochondria see references [8–10].
4.1. Translocation of signaling molecules to the mitochondria
Apparently the static picture of kinases and phosphatases
with a fixed localization to cellular compartments has to be at
least in part modified to a more dynamic model. There are
increasing numbers of signaling components that change their
sub-cellular localization upon alterations in the signaling state:
ubiquitously expressed tyrosine kinase c-Abl, which localizes to
the nucleus and cytoplasm, translocates from the endoplasmic
reticulum (ER) to the mitochondria, where it participates in the
induction of apoptosis; this was demonstrated after cells were
subjected to ER stress triggered with the calcium ionophore
A23187, brefedin A, or tunicamycin [162]. Epidermal growth
factor receptor translocates from the plasma membrane to the
mitochondria within 20 min after stimulation with epidermal
growth factor, where it interacts with CcO subunit II [91]. As
discussed in the Complex I section, PKA signaling goes along
with a translocation of AKAPs to the outer side of the outer
mitochondrial membrane. AKAPs not only provide a platform
for PKA signaling, but they also appear to be a hub for other
signaling pathways, converging signals to the mitochondria.
Livigni and coworkers [163] have recently shown that protein
tyrosine phosphatase PTPD1, and c-Src share the same scaffold
with PKA (Fig. 3). This model raises an interesting question
related to other studies discussed above that inferred localization
of PKA and c-Src to the inner compartments of the mito-
chondria. A co-existence of both models is possible, particularlyin a tissue-specific context. For example, c-Src localization to
the mitochondrial intermembrane space was demonstrated in
cells involved in bone formation that overexpress this kinase. In
other cell types with lower expression, c-Src might instead be
part of the signaling hub and stay on the outer side of the
mitochondria.
Akt (protein kinase B) localization to all compartments in the
mitochondria upon stimulation of the phosphoinositol-3-kinase
pathway was shown to be dynamically regulated [164].
Stimulation of cells with insulin-like growth factor-1, insulin,
and stress resulted in phosphorylation and activation of Akt,
followed by a fast accumulation in the mitochondria. The study
concluded that the β subunit of ATP synthase and glycogen
synthase kinase-3β were targets for phosphorylation by Akt.
Protein kinase Cδ (PKCδ) is a stress-activated kinase in-
volved in triggering the production of free radicals and the
induction of apoptosis. Translocation of PKCδ to the mitochon-
dria in mouse keratinocytes was shown after stimulation with 2-
O-tetradecanoylphorbol-13-acetate (TPA), which induced cell
death [165]. Translocation of PKCδ to the mitochondria does not
occur during ischemia, but was observed with 5 min of re-
perfusion applied after 30min ischemia in rat hearts, followed by
a decrease in mitochondrial respiration and an increase in
superoxide radical production [166].
Tyrosine phosphorylation in the mitochondria has recently
gained attention, in part because tyrosine kinases and phospha-
tases known to play pivotal functions in the cytosol or nucleus
also localize to the mitochondria [9]. Based on studies with rat
brain, Src and other Src family kinases Lyn, Fyn, Csk, and Fgr
were shown to localize to the mitochondrial intermembrane
space [9,43].
The presence of those tyrosine kinases not only raises the
question of their involvement in OxPhos regulation but also
implies the presence of tyrosine phosphatases. Protein phos-
phatase Shp-2 was the first identified tyrosine phosphatase that
localizes to the mitochondrial intermembrane space and the
outer mitochondrial membrane [167]. It represents another
example of dual localization because it is also a component of
the signaling scaffold located on the inner side of the plasma
membrane as part of the Ras pathway. Interestingly, mutations in
the PTPN11 gene, which encodes Shp-2, account for about 50%
of cases with Noonan syndrome [168], an autosomal dominant
disorder characterized by dysmorphic facial features, congenital
heart disease, short stature, webbed neck, chest deformity, and
mental retardation. In Noonan patients Shp-2 is constitutively
active [169], and it remains to be seen if disease pathology has a
mitochondrial component. Mitochondrial targets of Shp-2 are
currently unknown but due to their sub-mitochondrial co-
localization CcO tyrosine 304 [83] and Cyt c tyrosine 97 [62] are
possible candidate epitopes with known function, both leading
to activation of respiration in the unphosphorylated state. Inte-
restingly, calcium is believed to be a major activator of mito-
chondria, including OxPhos, and Shp-2 mutations were recently
shown to enhance calcium oscillations in cardiomyocytes [170].
Direct dephosphorylation of OxPhos components by Shp-2 or
indirect activation of OxPhos through calcium would lead to
increased respiration and an increase of the mitochondrial
Fig. 4. Toward a better understanding of the Warburg effect. During malignant
transformation cells switch from aerobic to glycolytic energy production.
Cancer cells require the supply of high levels of glucose, which is not only used
for fast energy production through the glycolytic pathway but is also essential
for the generation of building blocks for the rapidly dividing cell through the
pentose 5-phosphate pathway. It appears that the more aggressive and advanced
the cancer the less reliant it is on mitochondrial respiration. In addition the
balance between glycolysis and the pentose 5-phosphate pathway shifts toward
the latter, satisfying the increased demand for NADPH and five-carbon sugars
for biosynthesis.
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species (ROS), which are produced at elevated mitochondrial
membrane potential levels [153,171,172]. ROS play an
important role in organ development but the amount has to be
well controlled because fetal antioxidant activities such as
superoxide dismutase are depressed until just prior to parturition
[173], which might account for the increased ROS in fetal tissue
in certain pathological conditions [174]. The importance of a
narrow window of ROS production for proper heart develop-
ment and function was shown in a recent study using knockout
mice lacking the mitochondrial thioredoxin reductase, another
protective weapon against ROS [175]. The ubiquitous knockout
of the gene caused embryonic death after mid-gestation and
organ maldevelopment, including the heart, whereas cardiac
tissue-restricted inactivation of the gene resulted in fatal dilated
cardiomyopathy. Another relevant example is diabetes, where
oxidative damage caused by ROS was found in fetuses of dia-
betic rats, leading to congenital abnormalities, including ab-
normalities of the heart and great vessels, and neuronal damage
[176].
5. Cancer, apoptosis, free radicals, and neurodegenerative
diseases
Mitochondria seem to play an essential role in cancer pro-
liferation. Most solid tumors show a reduction in mitochondrial
mass of 25–60% compared to normal proliferating tissue [177].
This disequilibrium appears to signal the cell that it is in an
undifferentiated state, comparable to embryonic cells, which
show similarly low mitochondrial amounts [177]. Compared to
differentiated cells tumors rely less on respiration and more on
glycolysis, which is known as the Warburg effect [4,5].
The reasons cancer cells utilize glycolysis even in the pre-
sence of oxygen – what is known as aerobic glycolysis – are
currently being elucidated. One obvious factor appears to be an
enormous demand for energy in rapidly growing cells. Under
normal conditions mitochondria produce most cellular ATP.
However, respiration and in particular the shuttling of NADH
from the cytosol into the mitochondria are slow processes
(Fig. 4). Therefore, as long as glucose supply is unlimited, gly-
colysis allows considerably faster ATP production compared to
OxPhos [178].
Another key aspect of increased glycolysis results from its
linkage to the pentose phosphate pathway, which provides es-
sential building blocks for biosynthesis, such as the five-carbon
sugar ribose 5-phosphate and NADPH. Ribose 5-phosphate and
its derivatized forms are components of DNA, RNA, and the co-
factors ATP, NADH, FAD, and coenzyme A. NADPH is re-
quired for biosynthetic pathways, including fatty acid, choles-
terol, and nucleotide synthesis. The cell can adjust the amount
and ratio of pentose and NADPH production according to its
needs, because the pentose phosphate pathway is linked to
glycolysis through transketolase and transaldolase reactions,
which as a result allows the interconversion between five- and
six-carbon sugars. The increased utilization of the pentose
phosphate pathway in cancer cells compared to normal cells has
been elegantly demonstrated through metabolic studies using[1-14C]glucose and [6-14C]glucose followed by the determina-
tion of [14C]CO2 production [179]. The authors showed that
utilization of the pentose phosphate pathway was increased
fourfold in prostate tumors compared to normal cells, and more
than 12 times elevated in a poorly differentiated urothelial tumor
compared to normal urothelium, whereas a well-differentiated
urothelial tumor showed an intermediate, more than threefold
increase. One could speculate that the ratio of the two linked
pathways is a marker for cancer differentiation, staging, and
aggressiveness (Fig. 4).
Cancer cells require these major metabolic changes to deve-
lop a rapid and unrestricted proliferation, and the reduced
amount of mitochondria and the reduced capacity of the re-
maining mitochondria to respire might be interpreted as markers
for de-differentiation in cancers: the less differentiated the more
aggressive and the less reliant on mitochondrial respiration.
Interestingly, cancer therapy approaches, including ionizing
radiation and many of the chemical differentiation enhancing
agents, may act at least in part by increasing the mitochondrial
complement, and thereby returning the cell to the differentiated,
respiring, and non-proliferating state. This is so because such
agents aim at a transient nuclear cell cycle inhibition, which
suppresses mitochondrial DNA synthesis much less efficiently
[180].
Mutations in mitochondrial DNA (mtDNA) have been iden-
tified in many tumors (reviewed in [181]), and have been pro-
posed as a possible tool for cancer diagnosis [182]. Once
present, such mutations may enhance tumorigenesis as was
recently shown with cybrid cells containing the same nuclear
DNA in combination with or without mutant mtDNA [183].
However, in most cases mtDNA mutations are probably a
secondary event and not the cause of cancer.
It is now well established that cell signaling pathways are
dysregulated in cancers. Classic examples, which pointed to the
importance of signal transduction, are cancers caused by
viruses, such as the Rous sarcoma virus that infects chickens
and expresses a kinase, v-Src, homologous to the cellular kinase
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Another example is the Abelson murine leukemia virus
encoding the active v-Abl kinase that is homologous to the
cellular kinase c-Abl. Interestingly, as discussed above both Src
and Abl localize to the mitochondria, where they might directly
mediate the Warburg phenotype at the mitochondrial level after
viral infection. A further example is tumor suppressor and
transcriptional activator p53. p53 is regulated through cell sig-
naling and is very often mutated in cancers. Recently it was
shown that p53 regulates the expression of SCO2, a CcO as-
sembly factor, and that deletion of either p53 or SCO2 represses
mitochondrial respiration [184], perhaps through decreased
amounts of fully assembled CcO.
Mitochondria are emerging as a target for cancer therapy for
another reason: they are involved in apoptosis, a process that
cancer cells manage to evade. Mitochondrial or type II apoptosis
involves several proteins that are mostly localized on the
outside of the mitochondria such as anti-apoptotic proteins
Bcl-2, Bcl-xL, Mcl-1, and proapoptotic proteins Bax and Bak.
Bax and Bak are involved in pore formation after the induction
of apoptosis, which leads to the release of proteins located in
the mitochondrial intermembrane space including apoptosis
inducing factor (AIF) and OxPhos component Cyt c. Several
studies are underway testing chemical compounds that enhance
apoptosis (reviewed in [185]). For example Genasense™ is an
antisense oligonucleotide that targets and down-regulates anti-
apoptotic protein Bcl-2. Cells are then more susceptible to
apoptosis, which can be exploited by co-administration of a
standard chemotherapeutic drug.
A number of other anti-neoplastic compounds currently in
use or in (pre-)clinical testing including topoisomerase II inhi-
bitor etoposide, anti-microtubule agent taxol, and steroid mi-
metic CD437 also appear to directly target mitochondria [186].
The converging principle seems to be the release of Cyt c and
the induction of apoptosis, although the exact mechanisms
remain elusive in most cases.
Another mechanism by which the mitochondrial OxPhos
system appears to be involved in the carcinogenesis process is
increased free radical production. Free radicals are a byproduct
of the ETC, and increased levels lead to enhanced damage of
DNA, proteins, and lipids. Free radicals were thus proposed to
contribute to genomic instability and cancer progression. In-
creased free radical production can derive from dysfunctional
ETC complexes. This was recently shown for mutations in genes
encoding complex II subunits B, C, and D, which have been
associated with human paragangliomas that include head, neck,
and adrenal cancers [187]. It was shown that the introduction of
such a mutation of the C subunit into cultured B6 cells results in
significantly increased superoxide and hydrogen peroxide levels
and a fivefold increase in glucose uptake, another hallmark of
cancer metabolism [188].
The capability of complex II to produce free radicals may
also contribute to the pathology of Friedreich ataxia, an auto-
somal recessive neurodegenerative disease caused by mutations
in the frataxin gene. The frataxin protein is associated with the
inner mitochondrial membrane and was shown to directly inter-
act with complex II [189]. Dysfunctional frataxin might inducefree radical production, perhaps by interfering with complex II
assembly or by inducing structural changes in complex II.
Increased amounts of free radicals produced by the mitochon-
drial ETC are emerging as common factor in neurodegenerative
disease, including Parkinson's disease, Alzheimer's disease,
Friedreich ataxia, and multiple sclerosis. This can be at least in
part explained by the fact that neuronal tissue is highly aerobic
but at the same time very sensitive to oxidative damage due to
relatively low levels of antioxidants and antioxidant enzymes
(reviewed in [190]).
Dysfunctional mitochondria play an important role in various
neurodegenerative diseases. Among OxPhos complexes, signif-
icantly decreased activity of CcO above all was found in Al-
zheimer disease (AD) patients [191,192]. It was recently shown
that amyloid precursor protein accumulates in mitochondria of
AD patients, clogging the protein import machinery of the
mitochondria [193]. This mechanism can also explain decreased
protein levels of the core protein 1 of bc1 complex and the β-
chain of ATP synthase in AD patients [194], a pattern which is
also observed in patients with Parkinson's disease (PD). PD is
the most common neurodegenerative movement disorder.
Several PD mutations have been identified in genes that encode
proteins involved in mitochondrial function and regulation,
including α-synuclein, parkin, the mitochondrial kinase PINK1,
and the mitochondrial protease OMI (reviewed in [195]). In-
terestingly, α-synuclein, the major component of Lewy bodies
found in PD patients, was shown to interact with CcO by yeast
two-hybrid and co-immunoprecipitation studies [196]. A
general mechanism underlying dopaminergic cell loss as found
in PD patients might be increased cellular stress and ROS
production leading to cell death over time.
6. Concluding remarks
A large and still increasing number of human diseases are
associated with a dysfunctional OxPhos machinery. The two
distinct key factors involved are a lack of energy and increased
free radical production. Because of the central role of OxPhos in
cellular function the activity of its components has to be tightly
regulated and fine-tuned, as is clear from considering develop-
mental and tissue-specific energy requirements, and as is also
seen in the expression of subunit isoforms in CcO. Moreover,
higher organisms have to adapt to a constantly changing meta-
bolic environment, as seen in distinct states such as during
starvation, feeding, and exercising. Adaptation to those condi-
tions requires communication between cells and organs and is
mediated through hormones and electrical signals that activate
cell signaling cascades. Since the first reports on the phosphor-
ylation of OxPhos components more than a decade ago the
importance of this new field is increasingly recognized because
it is the link between physiology at the organismal level and
molecular changes within the mitochondria. Only 14 phosphor-
ylation sites have been mapped to date (Table 1) and the
functional consequences of most of these events have yet to be
studied. One would expect co-regulation of OxPhos components
under certain conditions, and we recently proposed that this may
be the case for Cyt c and CcO, which share 5 out of 10 amino
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phosphorylation sites and to study mitochondrial function in a
physiologically meaningful context, standard protocols to
isolate mitochondria have to be modified in order to prevent
dephosphorylation during the isolation of mitochondria and
OxPhos enzymes. Such protocols are available [62,83], although
additional optimization may further increase the yield of phos-
phorylated protein species, which is desirable for both mapping
of phosphorylation sites and functional studies. As a next step,
discovery of kinases and phosphatases that act on OxPhos is
necessary to reconstruct the intracellular signaling pathways.
Those signaling molecules could then become future targets for
therapy, in particular for the non-traditional mitochondrial
diseases, such as neurodegenerative diseases, diabetes, and
cancer. Current knowledge of cell signaling targeting OXphos
constitutes the tip of the iceberg, and major discoveries can be
expected that will revolutionize our understanding of the
regulation of energy production, free radical generation, and
apoptosis.
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